---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003617"
form_type: "8-K"
ticker: "BBNX"
cik: "0001674632"
company_name: "Beta Bionics, Inc."
filed_at: "2026-05-21T20:06:17+00:00"
generated_at: "2026-05-21T22:24:19.844039+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Beta Bionics targets Q2 2027 commercialization for Mint patch pump

## Summary
- Expects full commercialization of Mint patch pump by end of Q2 2027, subject to FDA clearance.
- Timeline based on FDA initial responses to 510(k) ACE insulin pump application and manufacturing scale progress.
- Mint features: 200-unit reservoir, 3-day wear, waterproof, smartphone controlled, no recharging needed.
- Compatible with Beta Bionics' iAGC algorithm and Dexcom G7, Abbott FreeStyle Libre 3 Plus CGMs.
- Exclusively available in pharmacy channel; manufacturing capacity expected to meet launch demand.

## SEC filing metadata
- accession: 0001171843-26-003617
- form_type: 8-K
- ticker: BBNX
- cik: 0001674632
- company_name: Beta Bionics, Inc.
- filed_at: 2026-05-21T20:06:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674632/000117184326003617/0001171843-26-003617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674632/000117184326003617/f8k_052126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003617
- JSON: https://secwatch.observer/filing/0001171843-26-003617.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.